Brefeldin A-induced apoptosis in prostatic cancer DU-145 cells: A possible p53-independent death pathway

BJU International

Volumn 83, Issue 6, 1999, Pages 703-708

  Chapman, J R ^a   Tazaki, H ^a   Mallouh, C ^a   Konno, S ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

Apoptosis; Brefeldin A; Cell cycle; Du 145 cells; Prostate cancer

Indexed keywords

BREFELDIN A; CYCLIN D1; DNA; PROTEIN KINASE; PROTEIN P53;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL COUNT; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL VIABILITY; CONTROLLED STUDY; DNA DETERMINATION; FLOW CYTOMETRY; GEL ELECTROPHORESIS; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IN SITU HYBRIDIZATION; MALE; NUCLEOSOME; PRIORITY JOURNAL; PROSTATE CANCER;

EID: 0032914671     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-410X.1999.00973.x     Document Type: Article

References (20)

1. 1 McLeod DG. Antiandrogenic drugs. Cancer 1993; 71: 1046-9
2. 2 Davies P, Eaton CL. Regulation of prostate growth. J Endocrinol 1991; 131: 5-17
3. 3 Tamura G, Ando K, Suzuki S, Takatsuki A, Arima K. Antiviral activity of brefeldin A and verrucarin A. J Antibiot 1968; 21: 160-1
4. 4 Lippincott-Scwartz J, Yuan LC, Bonifacino JS, Klausner RD. Rapid redistribution of Golgi proteins into the ER in cells treated with brefeldin A. Evidence for membrane cycling from Golgi to ER. Cell 1989; 56: 801-13
5. 5 Shao RG, Shimizu T, Pommier Y. Brefeldin A is a potent inducer of apoptosis in human cancer cells independently of p53. Exp Cell Res 1996; 227: 190-6
6. 6 Konno S, Mordente JA, Chen Y, Wu JM, Tazaki H, Mallouh C. Effects of brefeldin A on androgen receptor-mediated cellular responses in human prostatic carcinoma LNCaP cells. Mol Urol 1998; 2: 7-11
7. 7 Mordente JA, Konno S, Chen Y, Wu JM, Tazaki H, Mallouh C. The effects of brefeldin A (BFA) on cell cycle progression involving the modulation of the retinoblastoma protein (pRB) in PC-3 prostate cancer cells. J Urol 1998; 159: 275-9
8. 8 Horoszewicz JS, Leong SS, Kawinski E et al. LNCaP model of human prostatic carcinoma. Cancer Res 1983; 43: 1809-18
9. 9 Kaighn ME, Narayan KS, Ohnuki Y, Lechner JF, Jones LW. Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest Urol 1979: 17: 16-23
10. 1 cyclins. Cell 1993; 73: 1059-65
11. 11 Stone KR, Mickey DD, Wunderli H, Mickey GH, Paulson DF. Isolation of a human prostate carcinoma cell line (DU 145). Int J Cancer 1978; 21: 274-81
12. 12 Carroll AG, Voeller HJ, Sugars L, Gelmann E. p53 oncogene mutations in three human prostate cancer cell lines. Prostate 1993; 23: 123-34
13. 13 Gong J, Traganos F, Darzynkiewicz Z. A selective procedure for DNA extraction from apoptotic cells applicable for gel electrophoresis and flow cytometry. Anal Biochem 1994; 218: 314-9
14. 14 Rokhlin OW, Bishop GA, Hostager BS et al. Fas-mediated apoptosis in human prostatic carcinoma cell lines. Cancer Res 1997; 57: 1758-68
15. 15 Russo T, Zambrano N, Esposito F et al. A p53-independent pathway for activation of WAF1/CIP1 expression following oxidative stress. J Biol Chem 1995; 270: 29386-91
16. 16 Gartenhaus R, Wang P, Hoffmann P. Induction of the WAF1/CIP1 protein and apoptosis in human T-cell leukemia virus type I-transformed lymphocytes after treatment with adriamycin by using a p53-independent pathway. Proc Natl Acad Sci USA 1996; 93: 265-8
17. 17 Arends MJ, Morris RG, Wyllie AH. Apoptosis: The role of the endonuclease. Am J Pathol 1990; 136: 593-608
18. 18 El-Deiry WS, Tokino T, Velculescu VE et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993; 75: 817-25
19. 1 cyclin-dependent kinases. Cell 1993; 75: 805-16
20. 20 Waga S, Hannon GJ, Beach D, Stillman B. The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature 1994; 369: 574-8